- « Previous
- 1
- 2
IMPORTANT CORRECTION OF INVESTIGATIONAL DRUG INFORMATION
On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab. Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication. For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.